Autolus Therapeutics Stock Forward View - Accumulation Distribution
| AUTL Stock | USD 1.56 -0.04 -2.50% |
For short-term price forecasting, Autolus Therapeutics's sentiment profile - captured through news flow and social engagement - can be as informative as any financial ratio. This module quantifies and translates that data into a price signal.
According to momentum metrics, Autolus Therapeutics posts the 14-period RSI reading of 49, reflecting mild downside bias. This range suggests moderated price movement without extreme directional pressure.Momentum
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter -0.21 | EPS Estimate Current Year -0.99 | EPS Estimate Next Year -0.83 | Wall Street Target Price 8.99 | EPS Estimate Current Quarter -0.23 |
This section frames Autolus Therapeutics response to recent headlines in a peer context. Sentiment context here is built from Autolus Therapeutics' options activity and short interest data.
Short Interest Map for Autolus Therapeutics
Autolus Therapeutics' short interest, when combined with volume and price trend analysis, helps investors assess whether selling pressure in Autolus is likely to persist or abate.
200 Day MA 1.7433 | Short Percent 0.0785 | Short Ratio 9.57 | Shares Short Prior Month 15.9 M | 50 Day MA 1.5823 |
Autolus RSI Indicator
Hype-Price Trend View - Autolus Therapeutics
Autolus Therapeutics' market sentiment is a measurable proxy for investor optimism or fear. Monitoring changes in sentiment trend alongside price data gives early warning of potential reversals in Autolus.
For Autolus Therapeutics, sentiment-adjusted positioning means sizing exposure relative to how extreme the current market mood has become. High positive sentiment with elevated valuation is a classic signal to reduce risk.
Autolus Therapeutics Implied Volatility | 1.15 |
For long-term investors in Autolus Therapeutics, monitoring Autolus Therapeutics' implied volatility helps assess whether hedging costs are reasonable and whether the options market is pricing in unusually high uncertainty.
Autolus Therapeutics after-hype prediction price | $ 1.56 |
This view helps relate attention signals to forecasting and technical indicators plus earnings context.
Historical Fundamental Analysis of Autolus Therapeutics provides a cross-check on projections for Autolus Therapeutics. The analysis adds historical context for the projection set.Rule 16 Summary for current Autolus contract - Market Context
Rule 16 converts implied volatility into an estimated daily move of about 0.0719% for 2026-06-18 options. At a recent price around $ 1.56, the implied daily move is approximately $ 0.001121 , which is informational only.
Open Interest Coverage for 2026-06-18 Autolus Option Contracts
Outstanding Autolus Therapeutics options are captured via open interest, which provides contract-flow context.
Autolus Therapeutics Additional Predictive Modules
Most predictive techniques to examine Autolus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Autolus using various technical indicators. When you analyze Autolus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Previous Accumulation Distribution | Accumulation Distribution | Trend |
| 82836.86 | 65552.08 |
| Check Autolus Therapeutics Volatility | Backtest Autolus Therapeutics | Information Ratio |
Autolus Therapeutics Trading Date Momentum
| On March 11 2026 Autolus Therapeutics was traded for 1.56 at the closing time. The top price for the day was 1.63 and the lowest listed price was 1.54 . The trading volume for the day was 1.2 M. The trading history from March 11, 2026 did not affect price variability. The overall trading delta against the current closing price is 1.92% . |
Accumulation distribution indicator can signal that a trend is either nearing completion, at a continuation, or is about to break-outs. The actual value of this indicator is of no significance. What is significant is the change in value of over time. The formula for A/D of a given trading day can be expressed as follow: ((Close - Low) - (High - Close)) / (High - Low) X Volume
| Compare Autolus Therapeutics to competition |
Other Forecasting Options for Autolus Therapeutics
The price trajectory of Autolus is the primary concern for any investor assessing it as an opportunity. Autolus Stock price charts are filled with noise that can easily mislead uninformed investment decisions.Autolus Therapeutics Related Equities
The following equities are related to Autolus Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Autolus Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Autolus Therapeutics Market Strength Events
Understanding the market strength of Autolus Therapeutics stock enables investors to assess the security's momentum and responsiveness to broader market forces. These indicators are essential tools for timing trades in Autolus Therapeutics with greater precision.
| Accumulation Distribution | 65552.08 | |||
| Daily Balance Of Power | -0.44 | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 1.59 | |||
| Day Typical Price | 1.58 | |||
| Price Action Indicator | -0.04 | |||
| Period Momentum Indicator | -0.04 |
Autolus Therapeutics Risk Indicators
Reviewing Autolus Therapeutics' basic risk indicators is essential for investors who want to forecast its price and manage their investment risk effectively. This analysis helps identify the amount of risk involved in holding Autolus Therapeutics' and informs decisions about hedging and position.
| Mean Deviation | 3.49 | |||
| Semi Deviation | 4.9 | |||
| Standard Deviation | 4.62 | |||
| Variance | 21.38 | |||
| Downside Variance | 27.72 | |||
| Semi Variance | 24.04 | |||
| Expected Short fall | -3.48 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Autolus Therapeutics
Coverage intensity for Autolus Therapeutics matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Other Macroaxis Stories
Story coverage on Macroaxis is built for readers who approach markets from different levels of experience but share the same need for disciplined investment context. Used well, these stories become part of a broader workflow built around idea generation, validation, and risk-adjusted portfolio design.
Story Categories
Currently Trending Categories
Autolus Therapeutics Short Properties
Short sentiment tied to Autolus Therapeutics matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 255.2 M | |
| Cash And Short Term Investments | 588 M |
More Resources for Autolus Stock Analysis
A structured review of Autolus Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Autolus Therapeutics Stock. Highlighted below are reports that provide context for Autolus Therapeutics Stock:Historical Fundamental Analysis of Autolus Therapeutics provides a cross-check on projections for Autolus Therapeutics. The analysis adds historical context for the projection set. Explore our How to Trade Autolus Stock guide to learn how to trade Autolus Therapeutics effectively.Analysis related to Autolus Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Earnings Share -0.83 | Revenue Per Share | Quarterly Revenue Growth -0.11 | Return On Assets | Return On Equity |
Investors evaluate Autolus Therapeutics using market value and book value, each describing different facets of the business. Autolus Therapeutics' market capitalization is 415.18 M. A P/B ratio of 1.56 indicates the market values Autolus Therapeutics above its accounting book value. Enterprise value stands at 113.61 M. Intrinsic value is an estimate of what Autolus Therapeutics' fundamentals imply, and it may differ from market and book figures. Analytical frameworks help compare those viewpoints.
Value and price for Autolus Therapeutics are related but not identical, and they can diverge across cycles. For Autolus Therapeutics, key inputs include a P/B ratio of 1.56, ROE of -60.56%, and revenue of 10.12 M. By contrast, market price reflects the level where buyers and sellers transact.